Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Edwards Lifesciences Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Edwards Lifesciences Corp., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Net income (loss)
Depreciation and amortization
Non-cash operating lease cost
Stock-based compensation
Inventory write off
Impairment charges
Change in fair value of contingent consideration liabilities
Deferred income taxes
Purchase of intellectual property
Other
Accounts and other receivables, net
Inventories
Accounts payable and accrued liabilities
Income taxes
Prepaid expenses and other current assets
Litigation settlement accrual
Other
Changes in operating assets and liabilities
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Net cash provided by operating activities
Capital expenditures
Deposit of cash in escrow
Purchases of held-to-maturity investments
Proceeds from held-to-maturity investments
Purchases of available-for-sale investments
Proceeds from available-for-sale investments
Investments in intangible assets
Acquisitions
Payment for acquisition option
Issuances of notes receivable
Collections of notes receivable
Other
Net cash (used in) provided by investing activities
Proceeds from issuance of debt
Payments on debt and finance lease obligations
Purchases of treasury stock
Equity forward contract related to accelerated share repurchase agreement
Proceeds from stock plans
Payment of contingent consideration
Other
Net cash provided by (used in) financing activities
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash
Net increase (decrease) in cash, cash equivalents, and restricted cash

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Edwards Lifesciences Corp. net cash provided by operating activities increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Edwards Lifesciences Corp. net cash (used in) provided by investing activities decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Edwards Lifesciences Corp. net cash provided by (used in) financing activities increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.